Schrödinger, Inc. (SDGR) Company Overview

What does Schrödinger do?

Schrödinger, Inc. is a Nasdaq-listed molecular discovery company that combines scientific software with drug discovery. Its core asset is a physics-based computational platform used to predict molecular properties before researchers synthesize compounds in a laboratory. In plain English, the platform helps scientists search a much larger chemical space, reject weak ideas earlier, and concentrate experiments on molecules with better predicted potency, selectivity, safety, and manufacturability. The company describes this approach in its official company overview.

Why is the platform strategically unusual?

Schrödinger is not simply an artificial-intelligence software vendor. Its differentiation is the integration of machine learning with physics-based simulation that produces synthetic “ground truth” when experimental data are scarce. FEP+ estimates changes in binding affinity, Glide supports virtual screening, LiveDesign organizes multidisciplinary project decisions, and the broader computational platform connects those tools into a repeatable discovery workflow. This matters because molecular design has unusually high error costs: a promising prediction can still require months of synthesis, assays, and preclinical work before failure becomes visible.

How does Schrödinger make money, and which engine matters most?

The business model has two connected engines. Software customers pay for access to computational tools and enterprise workflows. Drug discovery partners pay Schrödinger to apply the same platform and scientific team to defined targets, while proprietary programs allow the company to retain more downstream value. The integration creates a useful strategic loop: internal and collaborative programs test the platform on difficult real-world problems, while software customers expand usage and fund continued platform development.

How are software contracts recognized?

On-premise licenses are generally recognized upfront when control transfers, while hosted contracts are recognized ratably over the contract term, typically one year. Maintenance and professional services add smaller streams. Schrödinger is deliberately accelerating the move toward hosted licensing, so reported software revenue can decline even when underlying contract value and cash economics improve. For that reason, annual contract value, or ACV, has become the cleaner measure of commercial momentum.

Why can drug discovery be more valuable than its revenue share suggests?

The drug discovery segment functions partly as a portfolio of options. By the end of FY2025, Schrödinger reported 16 ongoing programs eligible for royalties, 20 collaborators since 2018, more than 25 first-in-class, best-in-class, or first-in-modality programs across stages, and more than 10 clinical-stage programs. The company also said it had generated more than $650 million in cash from drug discovery initiatives since 2020 and remained eligible for nearly $5 billion of potential future milestones. Those headline values are not equivalent to contracted revenue: payments depend on scientific, regulatory, and commercial outcomes, and many milestones may never be earned.

What does Schrödinger’s latest quarter show?

The quarter ended March 31, 2026 shows the transition in unusually clear form. Total revenue slipped only 2%, but software revenue fell 21% because more customers shifted from upfront on-premise arrangements to hosted licensing. At the same time, first-quarter ACV grew 12% to $28.4 million and trailing-four-quarter ACV reached $201 million. Drug discovery revenue more than doubled, although part of the increase reflected accelerated recognition tied to the discontinuation of one collaboration program rather than a simple increase in successful milestones. The official first-quarter 2026 earnings release and Form 10-Q provide the underlying figures.

What is the cleanest read-through from the quarter?

The cleanest signal is that contract momentum looked better than GAAP software revenue. ACV rose, management cited usage scale-ups and new deployments, and the company maintained 2026 guidance for ACV of $218 million to $228 million, drug discovery revenue of $55 million to $65 million, and operating expenses below FY2025. However, the quarter also shows why investors must separate operating performance from accounting timing and investment marks. Q1 2026 free cash flow, calculated as operating cash flow minus property and equipment purchases, was approximately negative $17.3 million.

Why is the hosted-software transition central to the SDGR story?

Schrödinger is changing the timing and visibility of its largest revenue stream. In FY2025, hosted revenue was 23% of software revenue, up from 20% in FY2024. Management expects a majority of software contracts to transition to hosted agreements by 2028. Because hosted revenue is recognized over time rather than largely upfront, the shift can make near-term revenue and gross margin look weaker even if contract value, renewals, and cash collection remain healthy.

What changes economically, and what does not?

The strategic objective is credible but not automatic. Hosted delivery adds cloud-computing costs and may require commercial redesign, infrastructure investment, and customer migration support. Q1 2026 software gross margin of 69% was below FY2025’s 74%, partly reflecting the transition and approximately $1.4 million of higher cloud expense in software cost of revenue.

Which turning points explain Schrödinger’s strategy today?

Schrödinger’s history is best understood as a progression from specialist scientific software to an integrated software-and-therapeutics model. The company’s official history timeline highlights the product and business decisions that built today’s platform.

1. 1990
   Richard Friesner and Bill Goddard launched Schrödinger. Long-duration scientific investment became the foundation of the company’s present barrier to entry.
2. 2001
   Glide introduced high-throughput virtual screening, broadening the commercial usefulness of computational chemistry in pharmaceutical discovery.
3. 2009–2010
   WaterMap launched, Nimbus was co-founded, and an Agios collaboration began. These moves showed that software could create molecules and downstream economics, not only licenses.
4. 2012–2014
   The materials-science business launched, followed by FEP+ and LiveDesign. Schrödinger expanded from point tools toward an integrated prediction and collaboration platform.
5. 2018
   The company began building a proprietary drug pipeline, increasing potential retained value while adding clinical development costs and binary risk.
6. 2020
   Schrödinger became publicly traded on Nasdaq under SDGR, giving the company additional capital to invest in software, clinical programs, and collaborations.
7. 2023–2026
   Takeda’s Nimbus transaction, Lilly’s Morphic acquisition, the announced Ajax acquisition, and clinical progress at Structure validated the portfolio model, while the hosted migration and Bunsen initiative shifted attention back toward scalable software economics.

What strategic tension did this evolution create?

Schrödinger’s software can be evaluated like a vertical scientific-software franchise, but consolidated cash burn and valuation are also shaped by a biotechnology portfolio whose outcomes are episodic and uncertain.

That tension is both the attraction and the complexity. Drug discovery can validate the platform, produce milestones and royalties, and create equity value. Yet proprietary clinical programs consume R&D and can fail despite strong computational design. In August 2025, Schrödinger discontinued SGR-2921, demonstrating that “predict-first” discovery does not eliminate biological or clinical uncertainty.

What gives Schrödinger a competitive advantage, and who are its main rivals?

The moat is a bundle of accumulated scientific methods, validated workflows, customer trust, and specialized support rather than one patent or one model. More than three decades of R&D have produced tools that span docking, molecular dynamics, free-energy calculations, protein modeling, cheminformatics, and collaborative design. The company’s FY2025 customer evidence is notable: all top 20 pharmaceutical companies by 2024 revenue licensed Schrödinger solutions, contributing $73.7 million, or 37%, of software revenue and $80.8 million, or 41%, of ACV.

Which competitors pressure the software franchise?

Is the advantage durable?

It is durable only if Schrödinger keeps extending scientific accuracy and making the platform easier to use. Bunsen, the agentic AI co-scientist planned for early access in summer 2026, is intended to execute complex workflows autonomously and broaden the addressable user base beyond expert computational chemists. That could deepen usage, but it also enters a fast-moving market where AI interfaces may commoditize parts of the workflow. The moat therefore depends on proprietary science and validation beneath the interface, not the interface alone.

How financially strong is Schrödinger, and how is capital allocated?

Schrödinger has substantial liquidity but is not yet sustainably profitable. FY2025 revenue reached $255.9 million, gross profit was $142.6 million, and the operating loss was $166.9 million. Net loss improved to $103.3 million because equity-investment gains and other income partially offset operating losses. Operating cash flow was positive $13.9 million, but the result benefited from working-capital movements, including a $152.7 million decline in accounts receivable, so it should not be treated as steady-state free cash flow.

Where is cash being reinvested?

The FY2025 Form 10-K shows that capital allocation remains growth oriented: software R&D, cloud infrastructure, collaborative discovery, proprietary clinical programs, and selective equity stakes. Schrödinger has never paid a cash dividend and does not expect to do so in the foreseeable future. Management’s 2028 objective is positive adjusted EBITDA by year-end, supported by 10%–15% annual ACV growth, a substantially completed hosted transition, high-70s software gross margin, roughly $50 million of annual drug discovery revenue with timing variability, and lower expense intensity.

Who owns Schrödinger stock, and why does governance matter?

Schrödinger has dispersed public-company ownership alongside an unusual limited-common-stock structure. The April 1, 2026 beneficial-ownership table in the 2026 proxy statement lists several large institutional holders and significant founder and executive exposure. Common shares have one vote per share. Limited common shares also have one vote per share on most matters but cannot vote in director elections or removals; each can convert one-for-one into common stock.

What governance signals deserve attention?

The proxy also reported 12.40 million outstanding options, of which 11.10 million were underwater at the April 1, 2026 closing price. Equity compensation helps recruit scarce computational, software, and clinical talent, but investors should track the relationship between dilution, employee retention, and per-share value creation. Leadership continuity also matters: Ramy Farid remains president and CEO, Richie Jain became CFO in 2025, and Paul Davie is listed as chief commercial officer after the May 2026 commercial leadership change. The current leadership roster is available on the company’s official team page.

What opportunities and risks could change Schrödinger’s outlook?

The opportunity set is broad because the same platform can support software growth, higher-value enterprise deployment, materials discovery, collaborations, proprietary therapeutics, and equity-linked economics. The risk set is equally broad because Schrödinger must execute like both a software company and a biotechnology developer. Its most important strategic question is whether software operating leverage can emerge before clinical and platform reinvestment consume too much of the balance sheet.

Which growth drivers are most credible?

• Enterprise expansion: FY2025 ACV per commercial customer above $1 million rose 16.3% to $3.9 million, showing that depth within large accounts can offset customer-count variability.
• Top-pharma penetration: top-20 pharma ACV increased 15.3% to $80.8 million in FY2025, suggesting room to expand workflows even in already penetrated accounts.
• Bunsen and easier interfaces: autonomous workflow execution could broaden use beyond specialist computational chemists and increase platform throughput.
• Pipeline monetization: the official pipeline includes SGR-1505 and SGR-3515 plus collaborative programs eligible for milestones and royalties.
• Portfolio validation: announced or completed transactions involving Nimbus, Morphic, and Ajax provide external evidence that Schrödinger-enabled molecules can attract strategic buyers.

Which risks are most material?

Why does Schrödinger matter for valuation, and what is the key takeaway?

A conventional single-stage DCF is poorly suited to Schrödinger because the company combines a scaling software franchise with uncertain collaboration payments, proprietary clinical assets, and equity stakes. A more informative approach separates the recurring software economics from drug discovery optionality, then reconciles the pieces to consolidated cash requirements. The latest full-year results and 2028 objectives provide management’s operating bridge, but the assumptions still require independent testing.

What should researchers watch next?